Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lessened its position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 74.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 252,330 shares of the biotechnology company's stock after selling 748,727 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.22% of Coherus BioSciences worth $262,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Coherus BioSciences by 2,672.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 19,912 shares during the last quarter. TIAA Trust National Association purchased a new stake in shares of Coherus BioSciences in the second quarter valued at approximately $47,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Coherus BioSciences by 32.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 7,608 shares during the last quarter. Hsbc Holdings PLC lifted its position in Coherus BioSciences by 10.6% during the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company's stock worth $179,000 after buying an additional 9,905 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in Coherus BioSciences by 605.1% during the second quarter. SG Americas Securities LLC now owns 123,577 shares of the biotechnology company's stock worth $214,000 after buying an additional 106,052 shares during the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

Coherus BioSciences Trading Up 2.5 %

NASDAQ CHRS traded up $0.04 during trading hours on Wednesday, reaching $1.65. The company had a trading volume of 2,874,987 shares, compared to its average volume of 3,311,682. The stock has a market capitalization of $190.10 million, a P/E ratio of -20.63 and a beta of 0.86. The stock has a 50-day moving average of $1.02 and a 200 day moving average of $1.31. Coherus BioSciences, Inc. has a 1-year low of $0.66 and a 1-year high of $3.70.

Analyst Upgrades and Downgrades

CHRS has been the topic of several analyst reports. StockNews.com lowered Coherus BioSciences from a "buy" rating to a "hold" rating in a report on Saturday, October 19th. UBS Group downgraded shares of Coherus BioSciences from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $4.00 to $1.50 in a research note on Friday, August 16th. Robert W. Baird increased their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an "outperform" rating in a research note on Thursday, December 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Coherus BioSciences in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Coherus BioSciences currently has a consensus rating of "Moderate Buy" and an average price target of $5.38.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.